Capricor Therapeutics, Inc. (CAPR)
CAPR moved a median of -0.12% 30 minutes after news, and -0.32% by the close. How CAPR actually reacts to news — the realized, point-in-time move the market made, measured across 1,508 labeled events over the last three years with zero look-ahead.
CAPR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.00% | 50% | 1,484 |
| 30-min | -0.12% | 48% | 1,485 |
| 60-min | -0.26% | 46% | 1,485 |
| to close | -0.32% | 45% | 1,410 |
| Middle 50% of CAPR reactions | -1.26% to +1.66% |
|---|---|
| Median reaction (30-min) | -0.12% |
| Measured reactions | 1,508 |
Half of all Capricor Therapeutics, Inc. news events land between -1.26% and +1.66% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CAPR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -2.39% | 40% | -6.38% |
| Analyst downgrades | 23 | -0.16% | 30% | +35.60% |
| Coverage initiations | 19 | -0.12% | 37% | +1.60% |
| Rating reiterations | 86 | -0.15% | 44% | +0.07% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CAPR ranks against every other measured name →
That’s how CAPR usually reacts — get an email when it moves on news →Email me when CAPR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CAPR's baseline. Nothing else.
Recent CAPR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CAPR Lawsuit Alert: Capricor Therapeutics Investors Face September 28 Deadline After 64% Stock Drop Tied to Clinical Data Disclosure | Press release | PR Newswire | -1.64% | -0.98% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -1.64% | -0.98% | |
| Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data Disclosure -- Investors with Losses Notified to Contact BFA Law before September 28 Deadline | Press release | GlobeNewswire | -1.64% | -0.98% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -1.73% | -5.59% | |
| Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 | Press release | GlobeNewswire | +2.04% | -1.79% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -2.90% | +4.43% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -2.39% | +9.47% | |
| Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role | Press release | GlobeNewswire | +2.31% | +8.33% | |
| Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA | Press release | GlobeNewswire | -14.79% | -15.11% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -14.79% | -15.11% | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | -14.79% | -15.11% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -7.12% | -7.64% | |
| Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders | Press release | PR Newswire | -7.12% | -7.64% | |
| Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role | Press release | GlobeNewswire | +0.41% | +8.57% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -1.02% | +8.44% | |
| Form 10-Q CAPRICOR THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.02% | +8.44% | |
| Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -7.09% | -13.52% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | +0.57% | -0.24% | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -7.09% | -13.52% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.71% | +0.84% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.26% | — | |
| Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 | Press release | GlobeNewswire | -0.37% | — | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | -0.37% | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.37% | — | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.25% | +0.61% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | +2.32% | +7.73% | |
| Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026 | Press release | GlobeNewswire | +0.12% | +3.34% | |
| Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.25% | -1.50% | |
| Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws | Press release | GlobeNewswire | -0.48% | +0.12% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.78% | +8.53% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR | Press release | PR Newswire | +1.88% | +12.60% | |
| Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CAPR | Press release | Business Wire | +1.88% | +12.60% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.88% | +12.60% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.89% | +7.02% | |
| Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel | Press release | GlobeNewswire | +2.49% | +30.53% | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +12.87% | -4.70% | |
| Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws | Press release | GlobeNewswire | +0.13% | +9.69% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | — | — | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy | Press release | GlobeNewswire | — | — | |
| Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.50% | +10.23% | |
| Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel | Press release | GlobeNewswire | +0.61% | +9.13% | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -1.36% | |
| Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy | Press release | GlobeNewswire | -2.95% | -1.98% | |
| Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference | Press release | GlobeNewswire | -2.92% | -2.79% | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -6.44% | -11.88% | |
| Capricor Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -1.07% | -3.65% | |
| Form 8-K CAPRICOR THERAPEUTICS, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +1.70% | -1.92% | |
| Form 10-Q CAPRICOR THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.39% | -2.26% | |
| Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.94% | -0.72% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CAPR section they belong to.
Where else CAPR is measured.
CAPR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Mallinckrodt plc (MNK) | 1,580 | +0.04% | 53% |
| AmerisourceBergen Corporation (ABC) | 1,573 | +0.02% | 51% |
| CTI BioPharma Corp. (CTIC) | 1,481 | -0.33% | 39% |
| Elanco Animal Health Incorporated (ELAN) | 1,465 | +0.07% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Capricor Therapeutics, Inc.'s median reaction calculated?
Every labeled CAPR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,508 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of CAPR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does CAPR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.